scholarly journals The biological basis of degenerative disc disease: proteomic and biomechanical analysis of the canine intervertebral disc

2015 ◽  
Vol 17 (1) ◽  
Author(s):  
William Mark Erwin ◽  
Leroi DeSouza ◽  
Martha Funabashi ◽  
Greg Kawchuk ◽  
Muhammad Zia Karim ◽  
...  
Keyword(s):  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Biomechanical Analysis ◽  
Disc Disease ◽  
Biological Basis ◽  
Degenerative Disc

scholarly journals Cell-Based Therapies Used to Treat Lumbar Degenerative Disc Disease: A Systematic Review of Animal Studies and Human Clinical Trials

2015 ◽  
Vol 2015 ◽  
pp. 1-16 ◽  
Author(s):  
David Oehme ◽  
Tony Goldschlager ◽  
Peter Ghosh ◽  
Jeffrey V. Rosenfeld ◽  
Graham Jenkin
Keyword(s):  
Stem Cells ◽  
Clinical Trials ◽  
Low Back Pain ◽  
Back Pain ◽  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Low Back ◽  
Disc Disease ◽  
Degenerative Disc ◽  
Disc Regeneration

Low back pain and degenerative disc disease are a significant cause of pain and disability worldwide. Advances in regenerative medicine and cell-based therapies, particularly the transplantation of mesenchymal stem cells and intervertebral disc chondrocytes, have led to the publication of numerous studies and clinical trials utilising these biological therapies to treat degenerative spinal conditions, often reporting favourable outcomes. Stem cell mediated disc regeneration may bridge the gap between the two current alternatives for patients with low back pain, often inadequate pain management at one end and invasive surgery at the other. Through cartilage formation and disc regeneration or via modification of pain pathways stem cells are well suited to enhance spinal surgery practice. This paper will systematically review the current status of basic science studies, preclinical and clinical trials utilising cell-based therapies to repair the degenerate intervertebral disc. The mechanism of action of transplanted cells, as well as the limitations of published studies, will be discussed.

scholarly journals Chemometric evaluation of concentrations of trace elements in intervertebral disc tissue in patient with degenerative disc disease

2017 ◽  
Vol 24 (4) ◽  
pp. 610-617
Author(s):  
Łukasz Kubaszewski ◽  
Anetta Zioła-Frankowska ◽  
Zuzanna Gasik ◽  
Marcin Frankowski ◽  
Mikołaj Dąbrowski ◽  
...  
Keyword(s):  
Trace Elements ◽  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Disc Disease ◽  
Degenerative Disc ◽  
Disc Tissue

scholarly journals HISTOLOGICAL MARKERS OF DEGENERATION AND REGENERATION OF THE HUMAN INTERVERTEBRAL DISK

2017 ◽  
Vol 16 (1) ◽  
pp. 42-47
Author(s):  
MANUELA PELETTI-FIGUEIRÓ ◽  
ISRAEL SILVEIRA DE AGUIAR ◽  
SUELEN PAESI ◽  
DENISE CANTARELLI MACHADO ◽  
SERGIO ECHEVERRIGARAY ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Intervertebral Disc ◽  
Disc Degeneration ◽  
Degenerative Disc Disease ◽  
Intervertebral Disc Degeneration ◽  
Disc Disease ◽  
Lumbar Degenerative Disc Disease ◽  
Degenerative Disc ◽  
Hematoxylin And Eosin ◽  
Safranin O

ABSTRACT Objective: To define histological scores for intervertebral disc degeneration that would enable the definition of morphological characteristics of disease, besides improving knowledge of the lumbar degenerative disc disease by means of immunohistochemical markers. Methods: Hematoxylin and Eosin, Alcian/PAS, Masson Trichrome and Safranin O/FCF staining was used on the intervertebral disc degeneration sections of patients with lumbar degenerative disc disease. The protein markers defined in immunohistochemistry were cell proliferation (Ki-67) and apoptosis (p53). Results: The study data enabled the determination of Safranin O/FCF stain as the most effective one for evaluating parameters such as area, diameter, and number of chondrocyte clusters. The importance of using stains in association, such as Safranin O/FCF, Masson Trichrome, Alcian/PAS and Hematoxylin and Eosin, was also determined, as they are complementary for the histopathological verification of intervertebral disc degeneration. By expressing proteins using the immunohistochemistry technique, it was possible to consider two stages of disc degeneration: cell proliferation with chondrocyte cluster formation, and induction of apoptosis. Conclusion: This study enabled the histological and immunohistochemical characterization to be determined for lumbar degenerative disc disease, and its degrees of evolution, by determining new disc degeneration scores.

Pulmonary Impairment Rating

2016 ◽  
Vol 21 (4) ◽  
pp. 8-11
Author(s):  
Jay Blaisdell ◽  
James B. Talmage ◽  
Stephen Demeter
Keyword(s):  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Spinal Pain ◽  
Clinical Syndrome ◽  
Intervertebral Disc Herniation ◽  
Disc Disease ◽  
Degenerative Disc ◽  
Motion Segment ◽  
Objective Evidence ◽  
Disc Herniations

Abstract Nonspecific spinal pain and intervertebral disc herniations are common, and in evaluating spinal impairment physicians should carefully assess the significance of imaging findings, physical examination findings, and reports of limb pain. A case example illustrates key principles in assessing cervical pain in an individual with questionable arm complaints. A 62-year-old man had a slip and fall injury. Imaging studies revealed degenerative disc disease with disc bulges and without specific disc herniations according to the radiologists, but his physician reviewed magnetic resonance imaging (MRI) films and reported multiple disc herniations. The case example illustrates the significance of the finding of degenerative disc disease, determining whether to rate for “soft tissue and nonspecific conditions” or “motion segment lesions,” and assessing “nonverifiable radicular complaints.” The authors note that cervical degenerative disc “disease” is more aptly a radiologic diagnosis reflecting aging rather than a clinical syndrome and does not necessarily imply that the degenerative disc disease is the cause of the pain. To distinguish between nonverifiable radicular complaints without objective evidence of radiculopathy and unreliable vague complaints involving the extremity, evaluators should determine that the complaints are consistently and repetitively recognized in medical records and that they lie in the distribution of a single nerve root that the examiner can name. The diagnosis of “intervertebral disc herniation” cannot be made, and instead the “nonspecific chronic pain” diagnosis can be used. Nor can the diagnosis of alteration of motion segment integrity be used because the case lacks radiographically documented instability.

scholarly journals Impedance Therapy in Rehabilitation of Degenerative Disc Disease Randomized Clinical Trial

2019 ◽  
Vol 4 (11) ◽  
Keyword(s):  
Clinical Trial ◽  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Control Group ◽  
Average Increase ◽  
Disc Disease ◽  
Degenerative Disc ◽  
And Control ◽  
The Impact ◽  
Experimental Group

Aim: The aim of this work is to investigate the effects of Impedance Therapy (IT) in the treatment of degenerative disc disease by confirming the presence of the "disc grow-up" (DGU) phenomenon. Method: The set consisted of 55 patients with DDD with an average age of 51.3 years divided into two groups – the experimental group and control group. The experimental group consisted of 29 patients with an average age of 56.7 years. The control group consisted of 26 patients with an average age of 45.8 years. Results: In the experimental group of patients with DDD, who received IT, the DGU phenomenon with a success rate of 76% was observed, with an average increase in the volume of the intervertebral disc of 31% (p <0.000). In the control group of patients receiving standard electrotherapy, the DGU phenomenon was not proven – the DDD progressed normally with a mean volume reduction of 15% (p <0.000). Conclusions: Degenerative disc disease as a disease of modern civilization is treatable. It can be concluded that the theory, that degenerative disc changes are irreversible has been overcome by the impact of impedance therapy.

scholarly journals A Combinational Approach Using Cell Therapy, Tissue Engineering, and Distracting Device for the Treatment of Degenerative Disc Disease

2021 ◽  
Vol 7 (1) ◽  
pp. 1-5
Author(s):  
G Rasul Chaudhry ◽  
Keyword(s):  
Tissue Engineering ◽  
Cell Therapy ◽  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Organization Structure ◽  
Structure And Function ◽  
Disc Disease ◽  
Degenerative Disc ◽  
Vertebral Bodies ◽  
And Function

The Intervertebral Disc (IVD) is a fibrocartilaginous tissue instrumental in spine flexibility, allowing for the bending and twisting motion between vertebral bodies. Degenerative Disc Disease (DDD) results from the complex and chronic deterioration in IVD organization, structure, and function

scholarly journals Injectable Biologics for the Treatment of Degenerative Disc Disease

2020 ◽  
Vol 13 (6) ◽  
pp. 680-687
Author(s):  
Ajay Matta ◽  
W. Mark Erwin
Keyword(s):  
Intervertebral Disc ◽  
Degenerative Disc Disease ◽  
Strong Association ◽  
Vascular Supply ◽  
Small Sample ◽  
Large Animal ◽  
Systemic Delivery ◽  
Disc Disease ◽  
Degenerative Disc ◽  
Objective Evidence

Abstract Purpose of Review Spinal pain and associated disability is a leading cause of morbidity worldwide that has a strong association with degenerative disc disease (DDD). Biologically based therapies to treat DDD face significant challenges posed by the unique milieu of the environment within the intervertebral disc, and many promising therapies are in the early stages of development. Patient selection, reasonable therapeutic goals, approach, and timing will need to be discerned to successfully translate potential therapeutics. This review provides a brief overview of the status of intradiscal biologic therapies. Recent Findings Proposed systemic delivery of therapeutic agents has not progressed very much in large part due to the risk of adverse events in remote tissues plus the very limited vascular supply and therefore questionable delivery to the intervertebral disc nucleus pulposus. Intradiscal delivery of therapeutic proteins shows good potential for clinical trials and translation with encouraging results from large animal pre-clinical studies plus an enhanced understanding of the biology of DDD. There are a few cell-based therapies currently under pre-clinical and clinical trial investigation; however, these attempts continue to be hampered by unknown if any, mechanism of action, no downstream detection of transplanted cells, mixed results concerning efficacy, small sample numbers, and a lack of objective evidence of pain mediation. Summary Treatment of DDD using biologically based therapeutics is a widely sought-after goal; however, potential therapies need to address pain and disability in larger, well-controlled studies.

Sign in / Sign up

Export Citation Format

Share Document